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Abstract. The aim of the present study was to report a novel 
mutation in the retinoschisin 1 (RS1) gene in a Caucasian 
family affected by X-linked juvenile retinoschisis (XLRS) 
and to describe the long-term modification of retinal structure. 
Two brothers with an early onset maculopathy were diagnosed 
with XLRS. Fundus photography, fluorescein angiography, 
spectral domain optical coherence tomography and electro-
retinogram analyses were performed. Their sister was also 
examined. All subjects were screened for mutations in the 
RS1 gene. XLRS patients demonstrated a marked reduction 
of best-corrected visual acuity. SD-OCT scans reported a 
cystic degeneration primarily involving the inner nuclear layer, 
though some cysts were detected in the outer plexiform layer 
and in the ganglion cell layer. During the ten-year follow-up, 
a progressive retinal thickening and coalescence of the cysts 
was observed. Genetic testing revealed a novel mutation 
(p.Ile212Asn) in the RS1 gene in both XLRS patients, whereas 
their sister was not a genetic carrier. Several mutations of 
the RS1 gene were recognized to be responsible for XLRS. 
Although the correspondence between genotype and pheno-
type is still under debate, is reasonable that siblings affected 
by XLRS could share other genetic and/or epigenetic factors 
capable to influence clinical course of the disease.
Introduction
X-linked juvenile retinoschisis (XLRS, phenotype 
MIM 312700), first described in 1898 by Joseph Haas, repre-
sents the leading cause of early macular degeneration in 
males (1,2). Its prevalence ranges from 1:5,000 to 1:25,000 (3). 
Bilateral splitting of the inner retina is the most common 
clinical finding and has been reported in 68-100% of affected 
males. In ophthalmoscopy, the macula presents stellate spoke-
wheel pattern. Female carriers rarely present with retinal 
abnormalities (4). As the disease progresses, retinal cysts 
often coalesce with subsequent retinal flattening and macular 
atrophy in older patients. Peripheral schisis, usually located in 
the inferotemporal retina, is evident in ~50% of the affected 
individuals (5). Although this condition is considered to be 
congenital, symptoms generally present in the first decade of 
life with visual failure, squint or nystagmus. Visual damage 
usually progresses in the first two decades of life and remains 
approximately stationary until the fifth or sixth decade, when 
the development of macular atrophy induces additional visual 
loss (3).
Patients with XLRS present a characteristic pattern on the 
electroretinogram (ERG). A reduction in the amplitude of the 
b-wave (generated by the activity of depolarising bipolar cells) 
and a relative preservation of the negative a-wave (generated 
by photoreceptors) give rise to, the so-called electronega-
tive ERG (6). The absence of negative ERG does not necessarily 
exclude the presence of the pathology: in a series of 24 XLRS 
patients, only 56.5% presented with typical negative ERG (7).
Optical coherence tomography (OCT) is a key diagnostic 
test for XLRS. Schisis seems to occur predominantly at the 
inner nuclear layer (INL), occasionally at the outer nuclear 
layer/outer plexiform layer (ONL/OPL), and only rarely at 
the retinal nerve fiber layer (RNFL). The schisis cavity may 
extend beyond the retinal vascular arcades (8).
The gene responsible for XLRS, retinoschisin 1 (RS1), 
was identified by Sauer et al (2) in 1997. The RS1 gene, on 
chromosome Xp22, encodes for retinoschisin, a discoidin-
domain containing protein, which is secreted by photoreceptors 
and bipolar cells as a homo-oligomeric complex (2,9,10). 
Retinoschisin complex binds tightly to the surface of 
photoreceptors and bipolar cells, contributing to maintain the 
structural organization of the retina and of the photoreceptor-
bipolar synapse (4). In people with XLRS, several missense 
and nonsense mutations, insertion and deletion mutations, 
intragenic deletions and splice site mutations have been 
identified (11).
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The aim of the present study is to describe clinical features 
of a family affected by the novel missense mutation I212N 
of the RS gene and to provide a detailed follow-up based on 
spectral domain optical coherence tomography (SD-OCT).
Materials and methods
Patients. The present study included a Caucasian Italian 
family with two brothers clinically affected by XLRS. Both 
patients underwent a complete ophthalmological assessment 
and were followed up for ten years, including best-corrected 
visual acuity (BCVA) and fundus examination. Detailed 
multimodal retinal imaging (fundus photography, OCT, 
fundus autofluorescence (FAF) and retinal angiography) was 
collected. Moreover, retinal function was evaluated with ERG 
and Goldmann perimetry. Clinical and genetic testing was 
extended to other family members. The current study was 
conducted in accordance with The Declaration of Helsinki.
XLRS1 gene analysis. Written informed consent for genetic 
analysis was obtained from the all subjects. Whole blood 
samples were then collected. DNA was extracted using the 
Qiagen Biorobot DNA extraction kit (Qiagen, Inc., Valencia, 
CA, USA) according to manufacturer's instructions and quan-
tified by Nanodrop spectral analysis (Thermo Fisher Scientific, 
Inc., Waltham, MA, USA). DNA fragmentation and degrada-
tion were evaluated by standard agarose gel electrophoresis. 
A total of 100 ng DNA were amplified by standard poly-
merase chain reaction (PCR) procedures with a PCR mixture 
containing 2.5 µl 10X concentrated PCR buffer (Solis BioDyne, 
Tartu, Estonia), 0.7 µl 50 mM MgCl2 (Solis BioDyne), 0.75 µl 
10 mM deoxyribonucleotide triphosphates (Solis BioDyne), 
0.3 µl 100 µM forward primer and 0.3 µl of 100 µM reverse 
primer (primer sequences are listed in Table I) (Integrated 
DNA Technologies, Coralville, IA, USA) and 0.5 µl 5 U/µl 
Hot Start DNA Polymerase (Solis BioDyne). Thermocycling 
consisted of one cycle of enzyme activation (at 95˚C for 
15 min), followed by 35 cycles of DNA amplification (at 95˚C 
for 45 sec, at 59˚C for 45 sec and at 72˚C for 1 min). PCR 
products were then separated by agarose gel electrophoresis 
(1.5% agarose gel in tris-borate-EDTA; Sigma-Aldrich; Merck 
KGaA, Darmstadt, Germany) and purified with Invisorb spin 
columns (Invitek, Inc., Hayward, CA, USA). PCR-purified 
products were re-amplified with terminating nucleotides 
using Big Dye Terminator v3.1 (Applied Biosystems; Thermo 
Fisher Scientific, Inc.). Sequencing analysis was performed 
with an ABI Prism 3100 Avant automated sequencer (Thermo 
Fisher Scientific, Inc.) equipped with 36 cm capillary array 
filled with POP6 polymer (Thermo Fisher Scientific, Inc.). 
Electropherograms were analyzed using Sequencing Analysis 
software (Applied Biosystems, version 5.1; Thermo Fisher 
Scientific, Inc.).
Results
Patients. Three members of a family with two brothers affected 
by XLRS were studied. The first proband was a 41-year-old 
male and complained of mild visual disturbance since the age 
of 9, where medical records reported a spoke-wheel appearance 
of the macula and a BCVA of 0.8. His medical history was 
unremarkable. At the first presentation, BCVA was 0.4 in 
oculus uterque and remained stable for all the follow-up (2007 
through to 2016). Fundus examination reported the typical 
spoke wheel appearance of the macula in both eyes. In the 
right eye, a peripheral schisis in the inferior-temporal retina 
reaching the vascular arcade was also observed. Macular 
abnormalities were best recognized with FAF that indicated 
hyper- and hypo-FAF arranged in a radial pattern. Fluorescein 
angiography did not reveal any late leakage and confirmed the 
non-exudative origin of macular cysts.
On first examination with OCT, macular thickness was 
significantly increased. OCT scans presented a cystic degenera-
tion, primarily involving the INL, though some small cysts were 
detected in the outer plexiform layer (OPL) and in the ganglion 
cell layer (GCL). In RE, peripheral scans documented retinal 
schisis extending inferiorly. The first OCT was acquired when 
the patient was ~31 years old and BCVA was already reduced. 
In the right eye, the ten-year follow-up demonstrated that there 
were no noticeable variations in retinal morphology or in the 
overall width of the peripheral schisis. However, the progres-
sive straining of retinal layers breaks up the wall of macular 
cysts, weakening the retinal structure. Indeed, in the left eye, 
there was a moderate reduction in central retinal thickness 
(from 448 µm to 402 µm) that precedes the late, atrophic stage 
of XLRS. Outer retinal layers (external limiting membrane, 
inner segment/outer segment junction and photoreceptor layer) 
demonstrated diffuse atrophic changes with no significant 
progression during the follow-up (Fig. 1). Goldmann perimetry 
indicated in RE an absolute scotoma superiorly, that matched 
the peripheral retinal schisis. The dark-adapted 0.01 ERG (rod 
response) was reduced. The dark-adapted 3.0 ERG (combined 
rod-cone response) showed a b/a ratio <1, which matched the 
definition of an electronegative ERG. The patient reported a 
delay in implicit time and a decrease in the amplitude of the 
b-wave in the light adapted 3.0 ERG. A delayed light adapted 
30 Hz flicker peak time and decreased amplitude was also 
present. The diagnosis of XLRS was proposed and all family 
members were then invited for eye examination. His brother 
was a 30-year-old male. The diagnosis of unspecified retinal 
Table I. Primer sequences.
Primer Sequence (5'-3')
RS1_exon 1F GGAAAGCCATCCACACAAAG
RS1_exon 1R GGTTAACTTGATGGGGCTCA
RS1_exon 2F TCCTGACCTCAAGTGATCTGC
RS1_exon 2R TTCTTCCAGAAGGGGTGTTG
RS1_exon 3F GGAGAAAACCCGCATTAACA
RS1_exon 3R GACGATGCATAAGGACTGAGTG
RS1_exon 4F CCACCACGCCAGTTAATTTT
RS1_exon 4R GCAAAGCAGATGGGTTTGTT
RS1_exon 5F ACAGAGGGCAGTGACAGGAG
RS1_exon 5R GGAGACAAGGCTCAGACTGC
RS1_exon 6F ACCCAGCACTGCAGTTACAA
RS1_exon 6R GGGCTAGCTCCAGAAAGGAA
F, forward; R, reverse.
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dystrophy was made when he was 8 years old and he presented 
with a initial visual loss associated with characteristic spoke 
wheel appearance of the macula. At the examination, BCVA 
was 0.5 in RE and 0.6 in LE and progressively decreased to 0.4 
in RE and 0.3 in LE during follow-up. Fundus examination, 
OCT and retinal angiography revealed the typical features 
of XLRS. An electronegative ERG further supported the 
diagnosis. First OCT scans presented irregular empty spaces 
in the INL. Some small cysts could be observed in the GCL. 
Atrophic changes involving outer retinal layers (external 
limiting membrane, inner segment/outer segment junction and 
photoreceptor layer) were recognizable. During the follow-
up, the OCT scans revealed a progressive enlargement and 
coalescence of the cysts located in the INL, with subsequent 
retinal thickening. Small cysts in the GCL did not show 
further enlargement. Atrophic changes of outer retinal layers 
remained stable during follow-up (Fig. 2).
Ophthalmologic examination of their sister (21 years old) 
and of their father (69 years old) was normal. Their mother 
was deceased, but no significant visual disturbances were 
reported, even though it was not possible to ascertain if she 
was a healthy carrier or if she developed a de novo mutation. 
Indeed, ocular diseases in their maternal grandfather were not 
reported. Then, the authors drew a genealogical tree based on 
available information (Fig. 3).
Genetic testing. Screening of RS1 by sequencing of 
PCR-amplified DNA identified a novel missense mutation in 
exon 6 in both XLRS patients. This mutation from A to T at 
nucleotide position 635 changes the nonpolar isoleucine to 
positively charged asparagine (p.Ile212Asn).
This substitution was predicted to be harmful to protein 
function by in silico analysis (Polyphen2=0.989; Fig. 3).
Discussion
Mutations in the RS1 gene are responsible for inherited and 
sporadic XLRS. To date 191 causative genetic variations have 
been identified. Among all described variations, missense 
mutations represent the most recurrent subtype (100 muta-
tions of 191). Mutations can affect all regions of the RS gene, 
although a substantial clustering is observed within the region 
coding for the discoidin domain (85 of 191) (4). The novel 
missense mutation that we found in the patients is capable to 
produce the typical clinical phenotype of XLRS, as it affects 
the discoidin domain of retinoschisin.
Retinoschisin is a 24-kDa protein expressed exclusively 
by photoreceptors and bipolar cells in the retina and pineal 
gland. RS1 is secreted as a soluble disulfide bond-stabilized 
octamer. Most of the monomer (157 amino acids) comprises a 
discoidin domain, a globular fold that is highly conserved in a 
Figure 1. First proband. Spoke wheel appearance of the macula as seen using (A1, A2) fundus autofluorescence and (B1, B2) fluorescein angiography (trans-
verse resolution, 14 µm). In the right eye is a recognizable peripheral schisis in the inferior-temporal retina as indicated by *). Optical coherence tomography 
scans at the first examination reported a cystic degeneration primarily involving the inner nuclear layer in the (C1) right eye and in the (C2) left eye. Some small 
cysts are visible in the ganglion cell layer and outer plexiform layer (arrows). In the ten-year follow-up, the (D1) right eye did not show significant variations of 
retinal thickness and of peripheral schisis width, whereas in the (D2) left eye, there is a little reduction in central retinal thickness, due to coalescence of retinal 
cysts and initial collapse of retinal structure (axial resolution, 6 µm).
PIERMAROCCHI et al:  RETINAL STRUCTURES IN X-LINKED RETINOSCHISIS244
family of extracellular or transmembrane proteins implicated 
in cell adhesion or cell-cell interactions. The high number 
of mutations within the discoidin domain indicates that it is 
essential for the normal function of this protein. Although the 
role of retinoschisin in the retina is not well understood, it has 
been hypothesized that it works as a cell adhesion protein to 
maintain the structural organization of the retina and of the 
photoreceptor-bipolar synapse (4,5,10,12).
Differential diagnosis of XLRS comprises cystic changes 
of the macula that could arise from exudative and degenerative 
disorders or abnormalities of the vitreoretinal interface. 
Degenerative cystoid maculopathies may be hereditary [XLRS, 
Enhanced S-Cone/Goldmann Favre Syndrome (ESCS/GFS)] 
or acquired [microcystic macular edema (MME)]. All these 
conditions do not show late leakage on fluorescein angiography.
ESCS/GFS is a recessive disorder caused by mutations in 
the NR2E3 gene. This gene encodes for a nuclear receptor 
expressed in the outer nuclear layer of the retina. It suppresses 
cone differentiation during embryogenesis, therefore loss of 
NR2E3 results in retinas with a decreased number of rod 
photoreceptors and an increase in cones, predominantly 
expressing the S-cone opsin (13). Time trend of macular cysts 
development in ESCS/GFS resemble what happens in XLRS. 
The progressive enlargement and coalescence of macular cysts 
in young adulthood is followed by resolution of the schisis 
and reduction of macular thickness (14). However, location 
of cystic spaces seems different from XLRS. The analysis 
of published images shows large confluent cysts in the outer 
retinal layer associated with small and well-demarcated cysts 
in the INL (15,16).
MME is a recently described OCT entity, characterized 
by the appearance of small retinal cysts in patients with 
optic neuritis and optic atrophy of various aetiology (multiple 
sclerosis, neuromielitis optica, glaucoma) probably due 
to retrograde synaptic degeneration. As in XLRS, MME 
cysts involve the INL, however they do not seem to enlarge 
significantly with time. Moreover in MME cysts are usually 
circumscribed to the parafoveal region (17,18), whereas in 
XLRS cystic degeneration may extend beyond the vascular 
arcades.
Diagnosis of XLRS in the patients of the present study 
was strongly supported by clinical and instrumental findings. 
Indeed both patients presented with the classical phenotype 
of XLRS, with spoke-wheel maculopathy, association 
with peripheral schisis and ERG b-wave suppression. 
Ophthalmological history, regarding age of onset of symptoms 
and visual decline follows the typical course described in 
literature (7). Visual symptoms begin in the first decade, and 
then visual function progressively decreases, remaining stable 
in the following 10 years.
SD-OCT images collected in the two patients documented 
the natural history of the disease, characterized by the forma-
tion of small cysts located in the INL that progressively enlarge 
and coalesce. Gradually, the stretching of the wall of macular 
cysts weakens the retinal structure leading to the collapse of 
the cysts. Small isolated cysts were also observed in the GCL 
and OPL that, differently from those located in the INL, do 
not seem to increase over time. The possible presence of small 
cysts not determining macular splitting have been previously 
described by Gregori et al (19), who also found similar empty 
spaces in the ONL and in the GCL. The same paper reported 
that macular schisis may occur also in the OPL (19). An immu-
nochemistry study (20) in the normal mouse eye detected 
retinoschisin protein in all retinal layers; this may explain why 
retinal schisis can develop in different layers, even if some 
layers (GCL and RNFL) seem relatively resistant. The foveo-
macular retinoschisis is usually located in the INL, while the 
extramacular schisis could be equally found in the INL, ONL 
and GCL/NFL (21). In the present study, cystic degeneration 
at the level of peripheral schisis in RE of the first proband was 
located in the INL (Fig. 1).
Since clinical and instrumental findings were highly 
suggestive for XLRS, the authors performed genetic analysis. 
The sequencing of the proband DNA, revealed the hemizygous 
Figure  2. Second proband. First optical coherence tomography scans in the (R1) right eye and (L1) left eye reported irregular cysts in the INL and some small 
cysts in the GCL (arrows). The ten-year follow-up displayed a progressive enlargement and coalescence of the cysts located in the INL with subsequent retinal 
thickening. Small cysts in the GCL remained unchanged (arrows). INL, inner nuclear layer; GCL, ganglion cell layer (axial resolution, 6 µm).
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missense mutation p.lle212Asn (c.635A>T) in the RS1 gene. 
The same mutation was identified in the proband's brother and 
has never been reported before. It consists in a substitution of 
the non-polar amino acid, isoleucine, with the polar amino 
acid, asparagine. The mutation is located in a domain in which 
several genetic alterations associated with XLRS has been 
found (positions p.206, p.209, p.211, p.213, p.2015 and p.219). 
Furthermore, the PolyPhen-2 predictor has given to this 
mutation a high likelihood of protein dysfunction.
Given the high number of RS1 mutations, several studies 
investigated a possible correlation between genotype and 
phenotype. Even though some reports describe a correlation 
between specific variations and the severity of clinical pheno-
type (22,23), the majority of published studies found that 
XLRS patients had relatively uniform clinical manifestations, 
although with great intra-familial variation in age at onset and 
progression (1,24-26).
Interestingly, the deletion of exon 1 and promoter region, 
which causes complete absence of retinoschisin, is associated 
with a wide variability of the phenotype, suggesting that other 
genetic and/or epigenetic factors are likely to act as significant 
phenotypic modifiers in XLRS (27,28).
The absence of leakage on fluorescein angiography in XLRS 
patients suggests that vascular hyperpermeability serves a 
minor role, if any, in the pathogenesis of the disease. However, 
both oral and topical carbonic anhydrase inhibitors (CAIs) 
have been used successfully in the management of XLRS. 
CAIs act both on retinal and RPE cell function by acidifying 
the subretinal space, decreasing the standing potential as well 
as raising retinal adhesiveness, probably by increasing RPE 
fluid transport (29).
A promising approach for XLRS treatment is gene 
therapy. The disease is an excellent candidate for gene therapy 
as the majority of mutations have been shown to lead to a 
complete deficiency of the secreted protein in the retinal 
structures. Genetic treatment studies, conducted in rabbits and 
mouse, with intravitreal administration of adeno-associated 
viral vector coding the human RS1 gene demonstrated an 
improvement in retinal structure and function (30,31). Other 
strategies comprise the intravitreal administration of adipose-
derived mesenchymal stem cells, genetically modified to 
secrete the human RS1 gene, or solid lipid nanoparticles 
inducing the expression of retinoschisin in photoreceptors. 
Both treatments demonstrated morphological and functional 
improvements in mouse models (32,33). Two phase I/II trials 
are testing safety and efficacy of adeno-associated viral vectors, 
called AAV8-scRS/IRBPhRS and rAAV2tYF-CB-hRS1, as a 
gene therapy approach in XLRS patients. Viral vectors have 
Figure 3. Family pedigree of a Caucasian family with (left) XLRS (left) and (right) p.Ile212Asn electropherograms. The first and second proband are named 
A and B, respectively, whereas their sister is named C. XLRS, X-linked juvenile retinoschisis.
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been demonstrated to be able to shuttle normal RS1 DNA into 
retinal cells. Results are expected from 2017 (34,35).
The present study describes long-term morphological and 
functional changes of XLRS patients affected by a novel RS1 
mutation. Although the correspondence between genotype 
and phenotype is still under debate, is reasonable that siblings 
affected by XLRS could share other genetic and/or epigenetic 
factors capable to influence clinical course of the disease and 
perhaps treatment response to upcoming genetic therapies.
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